BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Phase 1

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: Everolimus
Drug: BNC105P

Registration Number: NCT01034631

Lead Sponsor: Hoosier Cancer Research Network

Brief Summary: The purpose of this study is to determine whether BNC105P in combination with/following everolimus is effective in the treatment of progressive metastatic clear cell renal cell carcinoma following prior tyrosine kinase inhibitors.

Detailed Description: OUTLINE: This is a multi-center study.

Phase I: Patients will be accrued in the classic 3 patients per dose per cohort design, 21-day cycle

* Dose Level 1 Everolimus 10 mg BNC105P 4.2 mg/m2

* Dose Level 2 Everolimus 10 mg BNC105P 8.4 mg/m2

* Dose Level 3 Everolimus 10 mg BNC105P 12.6 mg/m2

* Dose Level 4 Everolimus 10 mg BNC105P 16 mg/m2

Phase II: Patients will be randomized 1:1 to Arm A or Arm B

Combination Arm A: Everolimus 10 mg + BNC105P MTD (from Phase 1 study) 21 day cycle

Sequential Arm B: Everolimus 10 mg 21 day cycle

* Patients to receive BNC105P monotherapy at 16 mg/m2 following progression or intolerable toxicity on everolimus therapy.

Karnofsky Performance Score (KPS) ≥70 within 7 days prior to registration for protocol therapy.

Life Expectancy: Not specified

Hematopoietic:

* White blood cell count (WBC) \> 3.5 K/mm3

* Hemoglobin (Hgb) \> 8.5 g/dL

* Platelets \> 100 K/mm3

* Absolute neutrophil count (ANC) \> 1.5 K/mm3

Hepatic:

* Total Bilirubin \< 1.25 x ULN

* Aminotransferase (AST and ALT) \< 2.5 x ULN

Renal:

* Serum Creatinine \< 2.5 x ULN (upper limit normal)

Cardiovascular:

* No significant cardiovascular events within 6 months (CVA, CAD, peripheral arterial obstruction, arrhythmias, cardiac dysfunction) of registration for protocol therapy

* No history of clinical CHF or LVEF \<50% by Echo (or MUGA) within 30 days prior to registration for protocol therapy.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 154

Inclusion Criteria

Histological or cytological proof of component (any percent) of clear cell RCC (renal cell carcinoma).
Metastatic or locally advanced unresectable RCC. NOTE: Prior nephrectomy is not mandatory.
Progressive disease after 1-2 prior VEGF-directed tyrosine kinase inhibitors (TKIs).
Measurable disease according to RECIST and obtained by imaging within 30 days prior to registration for protocol therapy.
Written informed consent and HIPAA authorization for release of personal health information.
Age > 18 years at the time of consent.
Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 4 weeks after treatment discontinuation.
Females of childbearing potential must have a negative pregnancy test within 7 days prior to registration for protocol therapy.

Exclusion Criteria

No active brain metastases. Patients with neurological symptoms must undergo a head CT scan or brain MRI to exclude brain metastasis within 30 days prior to registration on protocol therapy. NOTE: A patient with prior brain metastasis are eligible if they have completed their radiation treatment for brain metastasis ≥30 days prior to registration for protocol therapy, are off steroids, and are asymptomatic.
No other currently active malignancy.
No treatment with any investigational agent within 14 days prior to registration for protocol therapy. NOTE: If treated with investigational agent within 14 days prior to registration, AE must be resolved back to baseline.
Prior cancer treatment must be completed at least 14 days prior to registration for protocol therapy and the patient must have recovered from the acute toxic effects of the regimen. With the exception of Bevacizumab treatment, which must be completed 30 days prior to registration for protocol therapy.
Prior radiation therapy to < 25% of the bone marrow [see bone marrow radiation chart in the study procedure manual (SPM)] allowed if completed within 30 days prior to registration for protocol therapy.
Corrected QT interval (QTc) ≤ 450 msec at least 7 days prior to registration for protocol therapy.
No clinically significant infections as judged by the treating investigator.
No liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis.
No collecting duct, medullary or sarcomatoid histology.
No prior treatment with temsirolimus or everolimus in the phase II component of the study. NOTE: Prior treatment with these agents is permitted in the phase I component of the study.
No use of full dose, therapeutic anti-coagulation with warfarin or related anti-coagulants or unfractionated or low molecular weight heparins.
No uncontrolled hypertension (BP >150/100mmHg despite full doses of 1 anti-hypertensive medication).
No thrombotic event within 6 months (deep vein thrombosis, pulmonary embolism) of registration for protocol therapy.
No grade 2 or greater peripheral neuropathy.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Sequential Arm B:Everolimus followed by BNC105P Monotherapy	BNC105P	Sequential Arm B: Everolimus 10 mg, 21 day cycle Patients to receive BNC105P monotherapy at 16 mg/m2 following progression or intolerable toxicity on everolimus therapy.
Combination Arm A: Everolimus + BNC105P	BNC105P	Combination Arm A: Everolimus 10 mg, BNC105P MTD (from Phase 1 study) 21 day cycle
Combination Arm A: Everolimus + BNC105P	Everolimus	Combination Arm A: Everolimus 10 mg, BNC105P MTD (from Phase 1 study) 21 day cycle
Sequential Arm B:Everolimus followed by BNC105P Monotherapy	Everolimus	Sequential Arm B: Everolimus 10 mg, 21 day cycle Patients to receive BNC105P monotherapy at 16 mg/m2 following progression or intolerable toxicity on everolimus therapy.

Primary Outcome Measures

Name	Time	Method
Phase I: Maximum Tolerated Dose of BNC105P in Combination With Everolimus.	Until disease progression or unacceptable toxicity, up to 24 cycles or 24 months	Phase I
Phase I: Toxicities of BNC105P in Combination With Everolimus.	Until disease progression or unacceptable toxicity, up to 24 cycles or 24 months	Determine the toxicities of BNC105P in combination with everolimus. Drug-related treatment emergent adverse events by CTCAE grade 2 or greater are reported
Phase II: 6-month Progression Free Survival (PFS) With the Addition of BNC105P to Everolimus.	6 months	Improvement in 6-month PFS with the addition of BNC105P to everolimus. Progression is defined using RECIST criteria as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions

Secondary Outcome Measures

Name	Time	Method
Phase II: Progression Free Survival (PFS) With BNC105P Alone in Patients After Progressing on Everolimus.	12 months	Median time to progression for arm P participants who crossed over to BNC105P monotherapy after progression. Progression is defined per RECIST criteria as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions
Geometric Mean Half-life of BNC105 and BNC105P in Combination With Everolimus.	12 months	Determine the PK Profile for BN105P in combination with everolimus by calculating the geometric mean half-life of BNC105P
Phase I: Response Rate of BNC105P in Combination With Everolimus.	Until disease progression or unacceptable toxicity, up to 24 cycles or 24 months	Number of objective responses per RECIST criteria. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
Phase II: Response Rate With Combination Therapy Compared to Everolimus Alone	12 months	Objective response is defined as a confirmed CR or PR per RECIST criteria. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
Phase II: Adverse Events of Everolimus and BNC105P When Administered as a Combination or Sequential Regimen.	12 months	Determine adverse events of everolimus and BNC105P when administered as a combination or sequential regimen. Total number of serious and non-serious adverse events for Arm A and Arm B are summarized. Complete adverse event information is supplied in the Adverse Events reporting section.
Phase II: Overall Survival	60 months	Determine overall survival probability, up to a maximum of 5 years from registration for protocol therapy.
Exploratory Objective: Correlation of PFS With Biomarkers	6 months	Exploratory analysis of serum biomarkers were undertaken to generate a potential signature for response. The correlation with 6 month progression free survival P value for four plasma biomarkers is reported.

Trial Locations

Locations (107): Northwest Alabama Cancer Center
🇺🇸
Muscle Shoals, Alabama, United States
Genesis Cancer Center
🇺🇸
Hot Springs, Arkansas, United States
Providence Health System: Roy and Patricia Disney Family Cancer Center
🇺🇸
Burbank, California, United States
Compassionate Cancer Care Medical Group, Inc.
🇺🇸
Corona, California, United States
Compassionate Cancer Care Medical Group
🇺🇸
Riverside, California, United States
City of Hope
🇺🇸
Duarte, California, United States
Robert A. Moss, M.D., FACP, Inc.
🇺🇸
Fountain Valley, California, United States
California Cancer Associates for Research and Excellence
🇺🇸
Fresno, California, United States
Marin Specialty Care
🇺🇸
Greenbrae, California, United States
Good Samaritan Hospital
🇺🇸
Los Angeles, California, United States
Scroll for more (97 remaining)
Northwest Alabama Cancer Center
🇺🇸Muscle Shoals, Alabama, United States